By stimulating both GLP-1 and GIP receptors, tirzepatide effectively reduces appetite, prolongs fullness, enhances insulin sensitivity, and potentially boosts your metabolism
Fortunately, there may be a new weight loss medication on the market that can help
Patients with renal impairment can generally use semaglutide and tirzepatide without dose adjustment, though monitoring for dehydration from gastrointestinal side effects is important
The participants were monitored every six months for the first three years and annually afterwards
This is the more straightforward approach, but youll need to be ready for your appetite returning within one to two weeks
continued the medication stopped the medication Patients who stayed on the medication didnt just hold their weight off they continued losing during maintenance, dropping another 5 to 7% to reach 17.4% total weight loss on Wegovy and 25% on Zepbound